Emmaus Life Sciences Inc 's Cash & cash equivalent grew by 140.07 % in the Q4 2025 sequentially, while Current Liabilities decreased, this led to improvement in Emmaus Life Sciences Inc 's Quick Ratio to 0.05, Quick Ratio remained below Emmaus Life Sciences Inc average.

Within Major Pharmaceutical Preparations industry 490 other companies have achieved higher Quick Ratio than Emmaus Life Sciences Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 4081 to 5008.

Explain Quick Ratio?
How much Cash & cash equivalents EMMAW�s has?
What are EMMAW�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/EMMAW/financial-strength

https://api.csimarket.com/api/v1/companies/EMMAW/fundamentals

https://api.csimarket.com/api/v1/companies/EMMAW/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

EMMAW Quick Ratio	(Dec 31 2025) Q4	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3
Y / Y Current Liabilities Change	-37.62 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	69.48 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.05	Subscribe	Subscribe	Subscribe	Subscribe
EMMAW's Total Ranking	# 5008	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-35.55 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	140.07 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 491
Healthcare Sector	# 999
Overall Market	# 5008

Quick Ratio Statistics
High	Average	Low
3.53	0.58	0.01
(Dec 31 2017)		(Jun 30 2025)

Financial Statements
Emmaus Life Sciences Inc 's Current Liabilities	$ 40 Millions	Visit EMMAW's Balance sheet
Emmaus Life Sciences Inc 's Cash & cash equivalent	$ 2 Millions	Visit EMMAW's Balance sheet
Source of EMMAW's Sales		Visit EMMAW's Sales by Geography

Cumulative Emmaus Life Sciences Inc 's Quick Ratio

EMMAW's Quick Ratio for the trailling 12 Months

EMMAW Quick Ratio	(Dec 31 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-8.26 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-18.53 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.02	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3181	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-9.47 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	17.93 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to EMMAW Financial Strength Comparisons >> Go to Compare EMMAW Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in EMMAW's Current Liabilities to $40.01 millions, cumulative Quick Ratio to 0.02 below the EMMAW average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 391 other companies have achieved higher Quick Ratio than Emmaus Life Sciences Inc . While Quick Ratio overall ranking has improved so far to 3181, from total ranking during the twelve months ending second quarter 2025 at 3349.

Explain Quick Ratio?
How much Cash & cash equivalents EMMAW�s has?
What are EMMAW�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 392
Healthcare Sector	# 818
Within the Market	# 3181

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.99	0.59	0.02
(Jun 30 2018)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Pmgc Holdings Inc	0.15	$ 0.572 Millions	$ 3.942 Millions
Casi Pharmaceuticals inc	0.14	$ 7.348 Millions	$ 51.425 Millions
Aspire Biopharma Holdings Inc	0.13	$ 1.004 Millions	$ 7.593 Millions
Astrazeneca Plc	0.13	$ 6,869.000 Millions	$ 52,465.000 Millions
Abbvie Inc	0.12	$ 5,257.000 Millions	$ 43,289.000 Millions
Abvc Biopharma Inc	0.12	$ 0.746 Millions	$ 6.164 Millions
Cdt Equity Inc	0.12	$ 1.509 Millions	$ 12.820 Millions
Lexaria Bioscience Corp	0.11	$ 0.165 Millions	$ 1.463 Millions
Gsk Plc	0.11	$ 4,428.946 Millions	$ 41,130.339 Millions
Lakewood-Amedex Biotherapeutics Inc.	0.10	$ 0.236 Millions	$ 2.405 Millions
Celularity Inc	0.08	$ 6.175 Millions	$ 80.759 Millions
China Pharma Holdings Inc	0.07	$ 0.345 Millions	$ 4.701 Millions
Gridai Technologies Corp	0.06	$ 0.900 Millions	$ 15.159 Millions
Cytodyn inc	0.06	$ 4.982 Millions	$ 85.112 Millions
Cv Sciences Inc	0.06	$ 0.278 Millions	$ 4.921 Millions
Emmaus Life Sciences Inc	0.05	$ 2.127 Millions	$ 40.008 Millions
Shuttle Pharmaceuticals Holdings Inc	0.04	$ 0.334 Millions	$ 7.967 Millions
Provectus Biopharmaceuticals Inc	0.04	$ 0.251 Millions	$ 6.245 Millions
Northwest Biotherapeutics Inc	0.03	$ 3.040 Millions	$ 91.700 Millions
Lunai Bioworks Inc	0.03	$ 0.492 Millions	$ 17.267 Millions
Jaguar Health Inc	0.02	$ 0.968 Millions	$ 40.654 Millions
Os Therapies Incorporated	0.02	$ 0.270 Millions	$ 11.728 Millions
Rain Enhancement Technologies Holdco Inc	0.02	$ 0.214 Millions	$ 10.835 Millions

Date modified: 2026-10-07T14:51:17+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.